Molnupiravir Market Overview and Analysis
The Global Molnupiravir Market is projected to expand from USD 1.01 Billion in 2025 to USD 1.44 Billion by 2031, registering a CAGR of 6.09%
The Global Molnupiravir Market comprises the production, distribution, and commercialization of molnupiravir, an oral antiviral medication primarily indicated for the treatment of mild-to-moderate COVID-19 in high-risk adult patients. Developed through a collaboration between Merck & Co., Inc. (known as MSD outside the U.S.) and Ridgeback Biotherapeutics, molnupiravir works by introducing errors into the viral RNA replication process, thereby inhibiting SARS-CoV-2 proliferation. The market includes branded and generic formulations distributed through hospitals, pharmacies, and government procurement programs worldwide. The demand is influenced by COVID-19 infection waves, regulatory approvals, stockpiling initiatives, and antiviral treatment guidelines across developed and emerging healthcare systems.
Molnupiravir Market Latest Trends
The molnupiravir market has evolved alongside the global COVID-19 landscape, shifting from emergency pandemic-driven demand to strategic stockpiling and targeted therapeutic use. Governments increasingly integrate oral antivirals into preparedness plans for future outbreaks. Expansion of generic manufacturing licenses in emerging markets has improved accessibility and affordability. Regulatory reviews and updated treatment guidelines continue to shape prescription patterns. Combination antiviral strategies and comparative effectiveness studies against alternative COVID-19 treatments influence market positioning.
Segmentation: The Global Molnupiravir Market is segmented by Formulation Type (Capsules, Tablets and Oral Suspension), Indication (Mild-to-Moderate COVID-19 in High-Risk Adults, Pandemic Response Use and Off-Label Research Applications), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Government Procurement & Public Health Programs and Online / E-Pharmacy Platforms), Type (Branded Molnupiravir and Generic Molnupiravir), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report provides the value (in USD million) for the above segments.
Market Drivers
- Ongoing COVID-19 Variants and Preparedness
The continued emergence of COVID-19 variants sustains demand for effective oral antiviral treatments like molnupiravir. Although vaccination campaigns have reduced severe outcomes, breakthrough infections and high-risk patient populations necessitate therapeutic options. Governments maintain antiviral stockpiles as part of pandemic preparedness strategies, ensuring rapid response capacity during infection surges. Molnupiravir’s oral administration supports outpatient care, reducing hospitalization burdens. Public health agencies continue to evaluate and include antivirals in updated treatment protocols. The potential for future coronavirus outbreaks or similar viral threats further strengthens demand for broad-spectrum antivirals, positioning molnupiravir as an important component of global infectious disease management frameworks.
- Expansion of Generic Licensing and Global Access
Voluntary licensing agreements and technology transfer initiatives have enabled widespread generic production of molnupiravir, significantly improving affordability and accessibility. Manufacturers in India, Southeast Asia, Africa, and Latin America have increased supply, supporting national treatment programs. Reduced pricing enhances adoption in resource-limited settings, expanding the patient base. International health organizations and procurement agencies facilitate bulk purchasing agreements to ensure equitable access. This broader distribution network strengthens global antiviral preparedness and drives sustained revenue streams.
Market Restraints:
- Declining Pandemic Urgency and Treatment Alternatives
A key restraint for the molnupiravir market is the decline in pandemic-related emergency demand and increasing availability of alternative COVID-19 therapies. Vaccination coverage, improved immunity levels, and lower hospitalization rates have reduced reliance on emergency antiviral procurement. Competing oral antivirals and evolving clinical guidelines may limit prescription volumes in certain regions. Safety considerations, ongoing efficacy evaluations, and changing regulatory recommendations also influence usage patterns.
Socioeconomic Impact on Molnupiravir Market
Molnupiravir contributed significantly to global pandemic response efforts by providing an oral, outpatient treatment option that reduced hospitalization risk among high-risk individuals. Its availability eased pressure on healthcare systems, particularly in regions with limited hospital capacity. Broader access through voluntary licensing agreements supported equitable distribution in low- and middle-income countries. Economically, antiviral deployment minimized workforce disruption by reducing severe disease burden and shortening recovery times. Government procurement and public health investments stimulated pharmaceutical manufacturing and supply chain activities. While demand has stabilized, molnupiravir remains part of national preparedness frameworks, reinforcing healthcare resilience and mitigating socioeconomic disruption during viral outbreaks.
Segmental Analysis:
- Tablets segment is expected to witness highest growth over the forecast period
The Tablets segment is expected to witness the highest growth over the forecast period due to increasing preference for convenient, stable, and easily distributable oral dosage forms. Tablets offer advantages such as longer shelf life, simplified packaging, and cost-effective large-scale manufacturing compared to other formulations. Generic manufacturers in emerging markets are increasingly developing tablet versions to improve accessibility and affordability. Additionally, tablets enhance patient compliance in outpatient settings, supporting decentralized COVID-19 treatment strategies. As governments and healthcare providers prioritize scalable antiviral distribution systems, tablet formulations are likely to gain wider acceptance, contributing significantly to overall molnupiravir market expansion globally.
- Mild-to-Moderate COVID-19 in High-Risk Adults segment is expected to witness highest growth over the forecast period
The Mild-to-Moderate COVID-19 in High-Risk Adults segment is projected to witness the highest growth as treatment guidelines continue to emphasize early antiviral intervention for vulnerable populations. Elderly individuals and patients with comorbidities remain at greater risk of severe disease progression, sustaining demand for effective outpatient therapies. Molnupiravir’s oral administration enables early treatment outside hospital settings, reducing hospitalization rates and healthcare system burden. Ongoing emergence of viral variants and breakthrough infections further reinforce the importance of targeted antiviral therapy. Public health programs and updated clinical recommendations are expected to maintain steady prescription volumes within this high-risk patient segment.
- Hospital Pharmacies segment is expected to witness highest growth over the forecast period
The Hospital Pharmacies segment is expected to witness the highest growth due to structured procurement systems and direct alignment with clinical treatment protocols. Hospitals often initiate antiviral therapy immediately after diagnosis, ensuring timely intervention for high-risk patients. Institutional purchasing agreements and government supply contracts further strengthen hospital-based distribution channels. In many regions, molnupiravir availability is closely monitored and dispensed through hospital networks to ensure appropriate prescribing practices. Additionally, hospital pharmacies support both inpatient and supervised outpatient care, enhancing controlled access. As healthcare systems maintain preparedness strategies, hospital pharmacies are likely to remain a key distribution hub for antiviral medications.
- Generic Molnupiravir segment is expected to witness highest growth over the forecast period
The Generic Molnupiravir segment is anticipated to witness the highest growth due to expanded voluntary licensing agreements and increased manufacturing capacity across emerging markets. Generic versions significantly reduce treatment costs, improving accessibility in low- and middle-income countries. Governments and international procurement agencies favor generics for bulk purchasing and national stockpiling initiatives. Competitive pricing and broader distribution networks further drive market penetration. As pandemic-related emergency demand transitions into long-term preparedness planning, affordable generic formulations are expected to dominate supply. This shift supports equitable global access while sustaining overall market growth through higher volume distribution.
- North American Region is expected to witness highest growth over the forecast period
The North American region is expected to witness the highest growth due to strong healthcare infrastructure, proactive antiviral stockpiling strategies, and established regulatory pathways. The United States leads regional demand, supported by updated treatment guidelines and government procurement programs. Continued monitoring of COVID-19 variants and high-risk population management sustains prescription volumes. Additionally, advanced distribution networks and hospital-based care systems facilitate efficient antiviral deployment. Strategic investments in pandemic preparedness and infectious disease management further reinforce regional market expansion. With robust pharmaceutical manufacturing capabilities and research initiatives, North America is positioned to remain a significant contributor to molnupiravir market growth.
Molnupiravir Market Competitive Landscape
The competitive landscape of the molnupiravir market is shaped by originator companies, licensed generic manufacturers, and competing antiviral therapies. Merck & Co., Inc. and Ridgeback Biotherapeutics initially led commercialization, while voluntary licensing agreements expanded production globally. Generic pharmaceutical firms across Asia, Latin America, and Africa manufacture cost-effective versions for domestic and international markets. Competition also arises from alternative oral antivirals and monoclonal antibody therapies, influencing pricing and market share. Strategic collaborations, regulatory approvals, and government contracts remain central to competitive positioning. As pandemic urgency declines, companies focus on lifecycle management, geographic expansion, and antiviral portfolio diversification to sustain relevance.
The major players are:
- Merck & Co., Inc.
- Ridgeback Biotherapeutics
- Cipla Limited
- Dr. Reddy's Laboratories
- Sun Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals
- Hetero Labs Limited
- Aurobindo Pharma
- Lupin Limited
- Zydus Lifesciences
- MSN Laboratories
- Alkem Laboratories
- Strides Pharma Science Limited
- Beximco Pharmaceuticals
- Optimax Healthcare
- Natco Pharma
- Emcure Pharmaceuticals
- Biocon Limited
- Mylan N.V.
- Pfizer Inc.
Recent Development
- In 2021, Merck and Ridgeback Biotherapeutics received FDA Emergency Use Authorization for molnupiravir, enabling treatment of high-risk adults with mild-to-moderate COVID-19. The authorization expanded early outpatient antiviral access, increased demand, and accelerated adoption globally, reinforcing molnupiravir’s role in pandemic response and outpatient therapeutic strategies.
- Torrent Pharma launched Molnutor, its branded version of molnupiravir in India, following a voluntary licensing agreement with MSD. The DCGI-approved emergency use expanded access in low- and middle-income countries, increased antiviral availability, and strengthened global adoption, significantly contributing to molnupiravir market growth and COVID-19 treatment strategies.
List of Figures
Figure 1: Global Molnupiravir Market Revenue Breakdown (USD Billion, %) by Region, 2022 & 2029
Figure 2: Global Molnupiravir Market Value Share (%), By Segment 1, 2022 & 2029
Figure 3: Global Molnupiravir Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 4: Global Molnupiravir Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 5: Global Molnupiravir Market Value Share (%), By Segment 2, 2022 & 2029
Figure 6: Global Molnupiravir Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 7: Global Molnupiravir Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 8: Global Molnupiravir Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 9: Global Molnupiravir Market Forecast (USD Billion), by Others, 2018-2029
Figure 10: Global Molnupiravir Market Value Share (%), By Segment 3, 2022 & 2029
Figure 11: Global Molnupiravir Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 12: Global Molnupiravir Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 13: Global Molnupiravir Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 14: Global Molnupiravir Market Forecast (USD Billion), by Others, 2018-2029
Figure 15: Global Molnupiravir Market Value (USD Billion), by Region, 2022 & 2029
Figure 16: North America Molnupiravir Market Value Share (%), By Segment 1, 2022 & 2029
Figure 17: North America Molnupiravir Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 18: North America Molnupiravir Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 19: North America Molnupiravir Market Value Share (%), By Segment 2, 2022 & 2029
Figure 20: North America Molnupiravir Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 21: North America Molnupiravir Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 22: North America Molnupiravir Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 23: North America Molnupiravir Market Forecast (USD Billion), by Others, 2018-2029
Figure 24: North America Molnupiravir Market Value Share (%), By Segment 3, 2022 & 2029
Figure 25: North America Molnupiravir Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 26: North America Molnupiravir Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 27: North America Molnupiravir Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 28: North America Molnupiravir Market Forecast (USD Billion), by Others, 2018-2029
Figure 29: North America Molnupiravir Market Forecast (USD Billion), by U.S., 2018-2029
Figure 30: North America Molnupiravir Market Forecast (USD Billion), by Canada, 2018-2029
Figure 31: Latin America Molnupiravir Market Value Share (%), By Segment 1, 2022 & 2029
Figure 32: Latin America Molnupiravir Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 33: Latin America Molnupiravir Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 34: Latin America Molnupiravir Market Value Share (%), By Segment 2, 2022 & 2029
Figure 35: Latin America Molnupiravir Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 36: Latin America Molnupiravir Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 37: Latin America Molnupiravir Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 38: Latin America Molnupiravir Market Forecast (USD Billion), by Others, 2018-2029
Figure 39: Latin America Molnupiravir Market Value Share (%), By Segment 3, 2022 & 2029
Figure 40: Latin America Molnupiravir Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 41: Latin America Molnupiravir Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 42: Latin America Molnupiravir Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 43: Latin America Molnupiravir Market Forecast (USD Billion), by Others, 2018-2029
Figure 44: Latin America Molnupiravir Market Forecast (USD Billion), by Brazil, 2018-2029
Figure 45: Latin America Molnupiravir Market Forecast (USD Billion), by Mexico, 2018-2029
Figure 46: Latin America Molnupiravir Market Forecast (USD Billion), by Rest of Latin America, 2018-2029
Figure 47: Europe Molnupiravir Market Value Share (%), By Segment 1, 2022 & 2029
Figure 48: Europe Molnupiravir Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 49: Europe Molnupiravir Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 50: Europe Molnupiravir Market Value Share (%), By Segment 2, 2022 & 2029
Figure 51: Europe Molnupiravir Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 52: Europe Molnupiravir Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 53: Europe Molnupiravir Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 54: Europe Molnupiravir Market Forecast (USD Billion), by Others, 2018-2029
Figure 55: Europe Molnupiravir Market Value Share (%), By Segment 3, 2022 & 2029
Figure 56: Europe Molnupiravir Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 57: Europe Molnupiravir Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 58: Europe Molnupiravir Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 59: Europe Molnupiravir Market Forecast (USD Billion), by Others, 2018-2029
Figure 60: Europe Molnupiravir Market Forecast (USD Billion), by U.K., 2018-2029
Figure 61: Europe Molnupiravir Market Forecast (USD Billion), by Germany, 2018-2029
Figure 62: Europe Molnupiravir Market Forecast (USD Billion), by France, 2018-2029
Figure 63: Europe Molnupiravir Market Forecast (USD Billion), by Italy, 2018-2029
Figure 64: Europe Molnupiravir Market Forecast (USD Billion), by Spain, 2018-2029
Figure 65: Europe Molnupiravir Market Forecast (USD Billion), by Russia, 2018-2029
Figure 66: Europe Molnupiravir Market Forecast (USD Billion), by Rest of Europe, 2018-2029
Figure 67: Asia Pacific Molnupiravir Market Value Share (%), By Segment 1, 2022 & 2029
Figure 68: Asia Pacific Molnupiravir Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 69: Asia Pacific Molnupiravir Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 70: Asia Pacific Molnupiravir Market Value Share (%), By Segment 2, 2022 & 2029
Figure 71: Asia Pacific Molnupiravir Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 72: Asia Pacific Molnupiravir Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 73: Asia Pacific Molnupiravir Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 74: Asia Pacific Molnupiravir Market Forecast (USD Billion), by Others, 2018-2029
Figure 75: Asia Pacific Molnupiravir Market Value Share (%), By Segment 3, 2022 & 2029
Figure 76: Asia Pacific Molnupiravir Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 77: Asia Pacific Molnupiravir Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 78: Asia Pacific Molnupiravir Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 79: Asia Pacific Molnupiravir Market Forecast (USD Billion), by Others, 2018-2029
Figure 80: Asia Pacific Molnupiravir Market Forecast (USD Billion), by China, 2018-2029
Figure 81: Asia Pacific Molnupiravir Market Forecast (USD Billion), by India, 2018-2029
Figure 82: Asia Pacific Molnupiravir Market Forecast (USD Billion), by Japan, 2018-2029
Figure 83: Asia Pacific Molnupiravir Market Forecast (USD Billion), by Australia, 2018-2029
Figure 84: Asia Pacific Molnupiravir Market Forecast (USD Billion), by Southeast Asia, 2018-2029
Figure 85: Asia Pacific Molnupiravir Market Forecast (USD Billion), by Rest of Asia Pacific, 2018-2029
Figure 86: Middle East & Africa Molnupiravir Market Value Share (%), By Segment 1, 2022 & 2029
Figure 87: Middle East & Africa Molnupiravir Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 88: Middle East & Africa Molnupiravir Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 89: Middle East & Africa Molnupiravir Market Value Share (%), By Segment 2, 2022 & 2029
Figure 90: Middle East & Africa Molnupiravir Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 91: Middle East & Africa Molnupiravir Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 92: Middle East & Africa Molnupiravir Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 93: Middle East & Africa Molnupiravir Market Forecast (USD Billion), by Others, 2018-2029
Figure 94: Middle East & Africa Molnupiravir Market Value Share (%), By Segment 3, 2022 & 2029
Figure 95: Middle East & Africa Molnupiravir Market Forecast (USD Billion), by Sub-Segment 1, 2018-2029
Figure 96: Middle East & Africa Molnupiravir Market Forecast (USD Billion), by Sub-Segment 2, 2018-2029
Figure 97: Middle East & Africa Molnupiravir Market Forecast (USD Billion), by Sub-Segment 3, 2018-2029
Figure 98: Middle East & Africa Molnupiravir Market Forecast (USD Billion), by Others, 2018-2029
Figure 99: Middle East & Africa Molnupiravir Market Forecast (USD Billion), by GCC, 2018-2029
Figure 100: Middle East & Africa Molnupiravir Market Forecast (USD Billion), by South Africa, 2018-2029
Figure 101: Middle East & Africa Molnupiravir Market Forecast (USD Billion), by Rest of Middle East & Africa, 2018-2029
List of Tables
Table 1: Global Molnupiravir Market Revenue (USD Billion) Forecast, by Segment 1, 2018-2029
Table 2: Global Molnupiravir Market Revenue (USD Billion) Forecast, by Segment 2, 2018-2029
Table 3: Global Molnupiravir Market Revenue (USD Billion) Forecast, by Segment 3, 2018-2029
Table 4: Global Molnupiravir Market Revenue (USD Billion) Forecast, by Region, 2018-2029
Table 5: North America Molnupiravir Market Revenue (USD Billion) Forecast, by Segment 1, 2018-2029
Table 6: North America Molnupiravir Market Revenue (USD Billion) Forecast, by Segment 2, 2018-2029
Table 7: North America Molnupiravir Market Revenue (USD Billion) Forecast, by Segment 3, 2018-2029
Table 8: North America Molnupiravir Market Revenue (USD Billion) Forecast, by Country, 2018-2029
Table 9: Europe Molnupiravir Market Revenue (USD Billion) Forecast, by Segment 1, 2018-2029
Table 10: Europe Molnupiravir Market Revenue (USD Billion) Forecast, by Segment 2, 2018-2029
Table 11: Europe Molnupiravir Market Revenue (USD Billion) Forecast, by Segment 3, 2018-2029
Table 12: Europe Molnupiravir Market Revenue (USD Billion) Forecast, by Country, 2018-2029
Table 13: Latin America Molnupiravir Market Revenue (USD Billion) Forecast, by Segment 1, 2018-2029
Table 14: Latin America Molnupiravir Market Revenue (USD Billion) Forecast, by Segment 2, 2018-2029
Table 15: Latin America Molnupiravir Market Revenue (USD Billion) Forecast, by Segment 3, 2018-2029
Table 16: Latin America Molnupiravir Market Revenue (USD Billion) Forecast, by Country, 2018-2029
Table 17: Asia Pacific Molnupiravir Market Revenue (USD Billion) Forecast, by Segment 1, 2018-2029
Table 18: Asia Pacific Molnupiravir Market Revenue (USD Billion) Forecast, by Segment 2, 2018-2029
Table 19: Asia Pacific Molnupiravir Market Revenue (USD Billion) Forecast, by Segment 3, 2018-2029
Table 20: Asia Pacific Molnupiravir Market Revenue (USD Billion) Forecast, by Country, 2018-2029
Table 21: Middle East & Africa Molnupiravir Market Revenue (USD Billion) Forecast, by Segment 1, 2018-2029
Table 22: Middle East & Africa Molnupiravir Market Revenue (USD Billion) Forecast, by Segment 2, 2018-2029
Table 23: Middle East & Africa Molnupiravir Market Revenue (USD Billion) Forecast, by Segment 3, 2018-2029
Table 24: Middle East & Africa Molnupiravir Market Revenue (USD Billion) Forecast, by Country, 2018-2029
Research Process
Data Library Research are conducted by industry experts who offer insight on
industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager
and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Primary Research
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary Research
Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size Estimation
Both, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
